SEC Form NT 10-K filed by Traws Pharma Inc.

 

	OMB APPROVAL
	OMB Number: 3235-0058
	Expires: October 31, 2018
	Estimated average burden hours per response ... 2.50

	SEC FILE NUMBER
	001-36020
	CUSIP NUMBER

(Check one):

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

Traws Pharma, Inc.

Full Name of Registrant

Former Name if Applicable

12 Penns Trail

Address of Principal Executive Office (Street and Number)

Newtown, Pennsylvania, 18940

City, State and Zip Code

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

[ x ]
			(a)		The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
			(b)		The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
			(c)		The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Traws Pharma, Inc. (the "Company") is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K as of and for the year ended December 31, 2025 (the "Form 10-K"). The Company has determined that it is unable to file its Form 10-K within the prescribed time period without unreasonable effort or expense. As previously disclosed, the Company has incurred recurring operating losses since inception and is pursuing additional financing alternatives to support its operations and maintain compliance with Nasdaq Listing Rule 5550(b)(1) related to minimum stockholders' equity requirements. The Company has not yet entered into an agreement with a lender or financial institution. Management is actively pursuing potential financing transactions; however, none have been finalized as of the date of this filing. As a result, the Company requires additional time to assess the potential impact of any such transaction on the financial statements to be issued with Form 10 K, including management's evaluation and related disclosures regarding whether conditions or events, considered in the aggregate, raise substantial doubt about the Company's ability to continue as a going concern. Once the Company completes the foregoing assessment, KPMG LLP, the Company's independent registered public accounting firm, will need time to complete its audit procedures on such information. The Company is working diligently on the necessary steps to complete and file its Form 10-K and anticipates it will be able to file its Form 10-K within the 15-day extension period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

		Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.